About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

New Multiplex Test to Diagnose Tick-borne Diseases

by Shravanthi Vikram on February 17, 2018 at 6:47 PM
Font : A-A+

New Multiplex Test to Diagnose Tick-borne Diseases

A single blood test called the Tick-borne Disease Serochip (TBD Serochip) helps in identifying the pathogen that is responsible for causing Lyme disease and seven other tick-borne pathogens. The test was developed by scientists from the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health. The findings of the study are reported in journal Nature: Scientific Reports.

Advertisement


The researchers--who also include scientists from the Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases, Roche Sequencing Solutions, Farmingdale State College, and Stony Brook University--sought to improve on existing tests for tick-borne diseases (TBDs), which have limited diagnostic accuracy and cannot test for more than one infection simultaneously. Currently, diagnosis of Lyme disease, the most common TBD, requires two separate tests. This cumbersome approach also relies on subjective criteria for the interpretation of results, and accurately identifies fewer than 40 percent of patients with early disease and results in false positives in 28 percent of the time. The accuracy of the method used to diagnose TBDs Babesia, Anaplasma, Ehrlichia, and Rickettsia varies widely among testing laboratories. And for other tick-borne agents, specific blood tests are not yet available, or in the case of the potentially deadly Powassan virus or Heartland virus, are only performed in specialized laboratories.

"The number of Americans diagnosed with tick-borne disease is steadily increasing as tick populations have expanded geographically," says Rafal Tokarz, PhD. "Each year, approximately 3 million clinical specimens are tested for TBDs in the U.S. Nonetheless, the true incidence of TBDs is likely greatly underestimated, as patients with presumed TBDs are rarely tested for the full range of tick-borne agents, and only a fraction of positive cases are properly reported," adds Nischay Mishra, PhD. Co-lead authors Tokarz and Mishra are associate research scientists in the Center for Infection and Immunity.
Advertisement

The TBD Serochip can simultaneously test for the presence of antibodies in blood to more than 170,000 individual protein fragments. Version 1.0 can identify exposure to eight tick-borne pathogens present in the U.S., including Anaplasma phagocytophilum (agent of human granulocytic anaplasmosis), Babesia microti (babesiosis), Borrelia burgdorferi (Lyme disease), Borrelia miyamotoi, Ehrlichia chaffeensis (human monocytic ehrlichiosis), Rickettsia rickettsii (Rocky Mountain spotted fever), Heartland virus and Powassan virus. The researchers also included Long Island tick rhabdovirus, a novel virus they recently discovered in Amblyomma americanum ticks. As new tick-borne infectious agents are discovered, the TBD-Serochip will be modified to target them--a process the researchers say can be done in less than four weeks.

The TBD Serochip is also able to identify whether an individual is infected with more than one tick-borne pathogen. Individual ticks are frequently infected with more than one agent; Ixodes scapularis ticks alone can transmit at least five human pathogens. Evidence of exposure to other tick-borne pathogens in patients with Lyme disease has been well documented. In the new paper, the researchers report finding antibodies to another agent in 26 percent of blood specimens from patients with TBD.

In addition to its utility as a diagnostic platform, the TBD Serochip also provides a powerful research tool for studies of TBDs. The technology can be employed to discriminate individual antibody responses in patients with TBD and thus examine the interplay of TBD agents on disease manifestation and progression. It can also be used to assess the impact of genetic diversity of tick-borne pathogens on the host immune response.

"Diagnosing tick-borne illness is a difficult journey for patients, delaying effecting treatment," says senior author W. Ian Lipkin, MD, director of CII and John Snow Professor of Epidemiology at Columbia University's Mailman School of Public Health. "The TBD Serochip promises to make diagnosis far easier, offering a single, accurate test for eight different TBDs. Early detection of infection enables rapid and appropriate treatment."



Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Environmental Health

 Plants Filter Airborne Pollutants That Cause Cancer
The Ambius small green wall, which contains a variety of indoor plants, was shown to be quite successful at removing hazardous, cancer-causing pollutants.
Uncovering the Link Between Dirty Air and Premature Death
Public health measures to prevent air pollution could lead to positive effects on patients with heart failure.
Solving the Nitrate Puzzle: Contradictory Hazards and Benefits of Nitrate
Nitrate has brought in two contradictory results, where one study states that it could be heart-healthy while the other points to it as a cancer risk.
Are We Ready for the Future Health Impacts of Climate Mitigation?
Worsened air quality due to climate mitigation efforts could lead to respiratory and cardiovascular problems.
Are We Ready to Reduce Plastic Pollution by 80% by 2040?
Reduction in plastic pollution results in an increase of 700,000 jobs by 2040, significantly improving the livelihoods of millions of workers in informal settings.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

New Multiplex Test to Diagnose Tick-borne Diseases Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests